On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions.
The post Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings appeared first on MedCity News.
Leave a comment